C W Lees
Overview
Explore the profile of C W Lees including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
1087
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jenkinson P, Plevris N, Siakavellas S, Lyons M, Arnott I, Wilson D, et al.
J Crohns Colitis
. 2020 Aug;
14(9):1241-1247.
PMID: 32840295
Background: The use of biologic therapy for Crohn's disease [CD] continues to evolve, however, the effect of this on the requirement for surgery remains unclear. We assessed changes in biologic...
2.
Plevris N, Chuah C, Allen R, Arnott I, Brennan P, Chaudhary S, et al.
J Crohns Colitis
. 2019 Feb;
13(9):1111-1120.
PMID: 30768123
Background & Aims: Vedolizumab is an anti-a4b7 monoclonal antibody that is licensed for the treatment of moderate to severe Crohn's disease and ulcerative colitis. The aims of this study were...
3.
Jones G, Fasci-Spurio F, Kennedy N, Plevris N, Jenkinson P, Lyons M, et al.
J Crohns Colitis
. 2018 Nov;
13(4):442-450.
PMID: 30452618
Background And Aims: Magnetic resonance enterography [MRE] is the gold standard for assessing ileal inflammation in Crohn's disease [CD]. The aim of the present study was to correlate faecal calprotectin...
4.
Kennedy N, Warner B, Johnston E, Flanders L, Hendy P, Ding N, et al.
Aliment Pharmacol Ther
. 2016 Feb;
43(8):910-923.
PMID: 26892328
Background: Infliximab and adalimumab have established roles in inflammatory bowel disease (IBD) therapy. UK regulators mandate reassessment after 12 months' anti-TNF therapy for IBD, with consideration of treatment withdrawal. There...
5.
Kennedy N, Kalla R, Warner B, Gambles C, Musy R, Reynolds S, et al.
Aliment Pharmacol Ther
. 2014 Oct;
40(11-12):1313-23.
PMID: 25284134
Background: Thiopurines (azathioprine and mercaptopurine) remain integral to most medical strategies for maintaining remission in Crohn's disease (CD) and ulcerative colitis (UC). Indefinite use of these drugs is tempered by...
6.
Jones G, Kennedy N, Lees C, Arnott I, Satsangi J
Aliment Pharmacol Ther
. 2014 Jul;
40(3):323.
PMID: 25040750
No abstract available.
7.
Jones G, Kennedy N, Lees C, Arnott I, Satsangi J
Aliment Pharmacol Ther
. 2014 Apr;
39(11):1253-65.
PMID: 24738574
Background: Post-operative recurrence of Crohn's disease is an important management challenge, with 2-year recurrence rates defined by clinical, endoscopic and radiological parameters of up to 77%, 64% and 49%. Clinical...
8.
Rahier J, Magro F, Abreu C, Armuzzi A, Ben-Horin S, Chowers Y, et al.
J Crohns Colitis
. 2014 Mar;
8(6):443-68.
PMID: 24613021
No abstract available.
9.
Gomollon F, Chowers Y, Danese S, Dignass A, Haagen Nielsen O, Lakatos P, et al.
Aliment Pharmacol Ther
. 2014 Mar;
39(7):743-4.
PMID: 24588280
No abstract available.
10.
Letter: Azathioprine-induced pancreatitis and subsequent tolerance of mercaptopurine--authors' reply
Kennedy N, Lees C
Aliment Pharmacol Ther
. 2014 Jan;
39(4):440-1.
PMID: 24447316
No abstract available.